User:Mr. Ibrahem/Remdesivir

Remdesivir, sold under the brand name Veklury, is a antiviral medication used for COVID‑19. In the USA and EU, as of 2022, it is recommended for mild to moderate disease at risk of worsening, including those who require oxygen therapy. In November of 2020 the World Health Organization conditionally recommendation against its use for COVID-19, regardless of disease severity. It is given by injection into a vein for 3 to 10 days.

Common side effects include increased liver enzymes and nausea. Other side effects may include allergic reactions. It is unclear if use during pregnancy is safe; though breastfeeding appears okay. Remdesivir is converted by the body into GS-441524 triphosphate, a ribonucleotide analogue inhibitor of viral RNA polymerase.

Remdesivir was approved for medical use in Europe in July 2020 and the United States in October 2020. It was developed by Gilead Sciences and was originally studied for hepatitis C, Ebola, and Marburg infections. In the United States it costs about 2,600 USD for five days as of 2021. This amount in the UK costs about £2,040.